Particularly, authors observed that low levels of Fibroblast Growth Factor 19 (FGF-19), normally repressed in CD patients on a GFD, and anti-tTG positivity are associated with a higher prevalence of hepatic steatosis, supposing a direct role of BAs in hepatic steatosis pathogenesis [111]. This evidence concerns the gene FGF19 and fatty liver disease.